InsightRX GEMINI℠ is designed to save clinician time and eliminate the need for manual model filtering
SAN FRANCISCO, Aug. 27, 2024 — InsightRX – the leader in Bayesian model-informed precision dosing software – today announced the release of InsightRX GEMINI℠. Officially released to customers on July 30, 2024, this enhanced dose-selection algorithm for vancomycin was built from datasets of more than 384,000 treatment courses.
Clinical guidelines recommend dosing vancomycin based on area under the plasma drug concentration-time curve (AUC). Just as a one-dose-fits all strategy doesn’t balance therapeutic efficacy with drug toxicity, there is growing evidence that different patient populations are best described using different models. For model-informed dose selection, the model used needs to be sufficiently predictive, however reviewing the literature to assess which model best suits a patient is a time-consuming process.
In just one-click, InsightRX GEMINI℠ works by:
- Parsing out relevant patient data based on vancomycin’s pharmacokinetics (PK)
- Making an initial PK model selection from InsightRX’s validated catalog
- Accessing InsightRX’s real-world data network to match the treatment patient to similar historical patients to compare PK model performance
- Summarizing and reviewing learnings to objectively select the best performing PK model to determine dosing
The new algorithm is based on experience and research, following seven years of applying model-informed precision dosing (MIPD) to treat over one million patients. InsightRX GEMINI℠ automates the selection of the most effective vancomycin PK model at the start of therapy, using patient characteristics known to impact model performance, like body mass index (BMI) and age. Auto-selected models can reduce bias, and result in better overall performance – ensuring a consistent best-practice standardization across healthcare systems.
External validation of the algorithm in a separate dataset of 144,000 patients showed that following the InsightRX GEMINI℠ model selection increased model prediction accuracy by as much as 47% from baseline compared to a single-model approach.
InsightRX developed an algorithm to select the best model for for a given patient based on the model’s historic performance in similar patients, evaluating models in 130+ patient characteristic combinations. This innovative algorithm is born from the collaborative power of InsightRX’s seasoned data scientists and clinical pharmacy specialists, following in the footsteps of InsightRX’s recent release of the first commercially available precision dosing model for heparin on the market.
“Clinicians have been asking for a one-click application to select the best model to determine vancomycin dosing,” said Sirj Goswami, Ph.D., InsightRX CEO and co-founder. “InsightRX GEMINI℠ removes the manual patient-factor selection process, making the intervention process faster at the point of care.”
Learn more about InsightRX GEMINI℠ at ASHP Midyear (Dec 8-12 in New Orleans, LA), where the InsightRX team will be showcasing their newest products and features helping to enhance the impact of precision dosing.
About InsightRX
InsightRX is a healthcare technology company providing a cloud-based clinical decision support platform that applies quantitative pharmacology and AI to enhance therapeutic decision-making from phase I drug development to point of care. The company’s platform provides an individualized, predictive understanding of a patient’s response to treatment which enables an enhanced understanding of dose-effect response and toxicity for clinicians to improve medication effectiveness.
